We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tissue Regenix Group Plc | TRX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.50 | 0.82% | 61.50 | 08:00:27 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 61.50 | 61.50 | 61.50 | 61.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 05/9/2023 20:52 by pj84 Just caught up on today’s results presentation on the Investor Meet platform.They elaborated on the positive first half results and I took away the following key points. Due to operational efficiencies, they have increased the capacity of the phase 1 expansion from an anticipated $30m to $40m of revenue, which means they expect to push back their phase 2 expansion plans by 12 months from 2024 to end 2025 and the phase 2 expansion is expected to cost $3.6m to $3.8m. They were asked about the revolving credit facility which they explained had been increased from $5m to $10m and extended out to 2028. They explained that they don’t take that into account in their growth plans which they expect to fund from existing resources, but it makes sense to keep it. They were also asked when they expected to be PBT positive, and they said for regulatory reasons they couldn’t guide on that in this forum but they did mention todays finnCap research note which they said could be accessed free of charge by registering with them. I did that and the finnCap note shows an expected adjusted PBT for 2024 of £0.4m continuing the current growth trajectory and they have a target price of 120p |
Posted at 31/8/2023 07:56 by clocktower Let us look forward to the results and what news maybe bounced upon investors when they are disclosed.The TS stated they had sufficient cash for their current trading plans but will they raise funds for an new plan to expand, and was consolidating the real reason to enable a discounting raise to be able to be achieved? Bearing in mind the stated growth the shares are trading poorly imo. So what’s been holding them back? I will wait before investing, as I have mentioned before I believe there will be a heavily discounted raise. DYOR |
Posted at 21/4/2023 18:04 by cliffpeat @longshanks:) Know what you mean but Del boy is a fictional character and seldom "lucky". AND the re-positioned share price may attract more "serious" investors and add market-liquidity from which we may benefit in the near term. We shall see?? |
Posted at 18/4/2023 10:00 by clocktower You just have to look at the how poor the volumes have sunk after the first advice that there would be consolidation, the first few days after the notification we saw some big sells and decent volume - now that has passed the volumes look pretty poor, so imaging how poor they will be once consolidated.What tickles me is they remark " may also help" so not very sure about that are they or they would be saying "will help" - because I guess they know that it will neither reduce the spread or increase volumes" In fact I believe the opposite. DYOR " The Board anticipates that the [Share Reorganisation] may also help to make the Company's shares more attractive to investors and may result in a narrowing of the bid/offer spread, thereby improving liquidity." |
Posted at 12/4/2023 22:24 by pj84 Investment summary: Turning EBITDA-positive in 4Q’22 was a major milestone, and the leverage effect of expected sales growth in 2023 will become more apparent, highlighting the low rating on the shares. An EV/sales multiple of 4x 2024E sales generates a valuation of $139m/£112m. The board is proposing a 1-for-100 share consolidation to make the shares less unwieldy and to increase their attractiveness to investors. |
Posted at 24/1/2023 18:07 by carrotandstick I think 100:1 consolidation would just make it look more attractive in general. I think such a low price might be a turn off for some potential investors, and on the surface I can see why. |
Posted at 24/1/2023 13:51 by cyberbub A 100:1 consolidation would make it much more attractive to US investors. |
Posted at 15/1/2023 18:35 by curiousish Boystown - Christopher Mills does an interview on Vox markets every 6 months or so. The last one was in December. He uses the interviews to promote Harwood investments. Despite building a stake in TRX he evidently didn’t want to talk about it. The conclusion I reach is that he doesn’t want to promote it because he has plans to acquire more. The key for us investors is how he does that. Hopefully not a repeat of what happened at sourcebioscience. Time will tell. |
Posted at 03/1/2023 12:51 by cyberbub Remember it's a new tax year for the US - or more to the point it was the end of the old tax year last week, which always triggers some selling by US investors for tax balancing. As TRX is largely a US company I expect there will be plenty of US investors in it. |
Posted at 24/11/2022 15:10 by cyberbub I agree, when investing in risky smallcaps, often the most important thing to assess is not how much upside there is, but whether there is significant downside. While AIM investors need to always accept a 50% downside risk IMO, many AIM stocks have an 80-100% downside risk. With TRX, unless there is another pandemic, wider war, or the management make a complete balls-up of it, then there probably isn't a big downside risk (mid/long term) from 0.6p. Hopefully I haven't jinxed it now!!! :-o |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
